Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Operations (2024 - 2025)

Indivior Pharmaceuticals has reported Cash from Operations over the past 2 years, most recently at 221000000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 221000000.0 for Q4 2025, down 1200.0% from a year ago — trailing twelve months through Dec 2025 was 27000000.0 (down 175.0% YoY), and the annual figure for FY2025 was 27000000.0, down 175.0%.
  • Cash from Operations for Q4 2025 was 221000000.0 at Indivior Pharmaceuticals, down from 39000000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for INDV hit a ceiling of 158000000.0 in Q2 2025 and a floor of 221000000.0 in Q4 2025.